It’s a rallying cry Alderman Joe Kelly Levasseur said he’s heard over the past week from resident across the city and state, ...

GLP-1s aren't FDA-approved to treat rheumatoid arthritis, but many people notice improvement in their inflammation with the ...

GLP-1 meds are trending after Serena Williams’ 31-pound weight loss. A doctor breaks down the side effects, safety concerns & ...

A study has found that adults with obesity taking GLP-1 receptor agonists may face significantly lower risk of developing certain cancers. The cohort study was led by researchers from the Indiana ...

As cancer progression has been linked with high glucose, adiposity, insulin resistance, and systemic inflammation, investigators studied several glucose-lowering drugs in relationship to cancer ...

"Losing weight is a choice. But it should never be made because of society’s aesthetic obsession with thinness." ...

GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly ...

By now, you’ve probably heard about the weight-loss benefits of GLP-1 drugs like Ozempic (semaglutide ... The key policy question is how to push prices down even further. Denmark has been able to ...

Last year, GLP-1s dominated many employer conversations as demand surged and pressure mounted from employees clamoring for ...

GoodRx (NASDAQ:GDRX) jumped 18% after revealing a partnership with Novo Nordisk (NYSE:NVO) to offer Ozempic and Wegovy to eligible self-paying patients at a monthly price of $499. This agreement ...

As the Dec. 31 end to federal subsidies for federal health care nears, pressure is mounting on insurers, providers, and the ...

Drivers of revenue growth included more customers using multiple chronic condition programs as well as strong adoption of GLP ...